Introduction {#Sec1}
============

Gastric cancer is a complex, heterogeneous disease with a global variation in its aetiology, incidence, natural course, and management. The tumourigenic conditions of gastric cancers are associated with infectious agents (*Helicobacter pylori* or Epstein-Barr virus)^[@CR1],[@CR2]^, lecular subset (*CDH1* mutation)^[@CR3]^, and different levels of susceptibility and aggressiveness of the tumours. The clinical factors for determining a treatment plan are location of the primary tumour (proximal and distal), subtypes of adenocarcinoma (diffuse, intestinal, or mixed)^[@CR4]^, tumour susceptibility based on ethnicity, and predictive biomarkers (*HER2*)^[@CR5]^. Generally, the following prognostic indicators are considered in clinical management: American joint Committee on Cancer (AJCC) stage and size, histological type and grade, and lymphovascular and perineural invasion. A study by the Cancer Genome Atlas Research Network indicated that gastric cancers can be classified into four subtypes based on molecular characteristics: Epstein-Barr virus positivity, microsatellite instability, genomic stability, and chromosomal instability^[@CR6]^. However, these molecular analyses might be limited in general hospitals that lack facilities. Moreover, molecular markers are expensive and often time-consuming to measure. When there are sufficient technologists with an appropriate laboratory setting, genetic analyses to determine the new subtypes can be easily used in clinical application.

Systemic inflammation is associated with the progression of various cancers by induction of angiogenesis, metastasis and malignant cell proliferation, and alteration of the response to systemic therapy^[@CR7]^. Neutrophils are known to be key mediators of tumour inflammation^[@CR8]^ and angiogenesis^[@CR9]^. Lymphocytes have been suggested to play vital roles in cytotoxic tumour cell death linked to tumour-infiltrating lymphocytes, especially T lymphocytes^[@CR10]^. The interaction between the cancer and immune system might also extend beyond the local tissue environment. Other systemic inflammatory markers such as C-reactive protein and interleukin-6, have been associated with worse survival in patients with gastric cancer^[@CR11]^. The imbalance between neutrophils and lymphocytes is thought to be secondary to tumour hypoxia or necrosis and associated with anti-apoptotic effects. Published data demonstrated that the initial neutrophil-to-lymphocyte ratio (iNLR) at that time of first diagnosis is linked to prognosis of different types of cancer^[@CR12]--[@CR15]^ as well as of other conditions such as cardiovascular disease^[@CR16]^ and bacterial infection^[@CR17]^. Accordingly, the iNLR might represent the balance between pro-tumour inflammatory status and anti-tumour immune status.

Several studies focused primarily on iNLR, while the dynamic change of neutrophil-to-lymphocyte ratio after treatment was not considered. The postoperative neutrophil-to-lymphocyte ratio change (NLRc) might be a meaningful factor to assess prognosis after treatment, because there has been a change in the treatment approach including tumour removal and chemotherapy. However, although the NLRc might dynamically reflect the alteration of balance between host inflammatory response and immune response against cancer after treatment, its significance is largely unclear.

The aim of this study was to investigate the relationships between iNLR and NLRc and clinicopathological parameters, and to evaluate the prognostic value of the NLRc in patients with gastric cancer.

Results {#Sec2}
=======

Patient characteristics {#Sec3}
-----------------------

The median age of the 734 patients was 66 (range: 23--87) years. The following clinicopathological variables were recorded: Sex; age; 8^th^ AJCC stage; location; local recurrence; distant metastasis; size; Lauren type; histological grade; lymphatic, vascular, and perineural invasion; presence of adjuvant chemotherapy; margin involvement, and patient survival.

EGC was present in 395 patients and advanced gastric cancer (AGC) in 339. In early gastric cancer (EGC), the predominant gross type was classified as protruding (type I) in 21 patients, slightly elevated (type IIa) in 28, flat (type IIb) in 113, slightly depressed (type IIb) in 196, and excavated (type III) in 37. In AGC, the predominant gross type was classified as fungating (Borrmann type 1) in 11 patients, ulcerative (Borrmann type 2) in 66, ulcero-infiltrative (Borrmann type 3) in 221, and linitis plastica (Borrmann type 4) in 41. According to the Lauren classification, 396 patients had intestinal type, followed by 217 with a diffuse type and 121 with a mixed type. The surgical procedures included subtotal gastrectomy in 567, total gastrectomy in 106, endoscopic submucosal dissection in 54, and endoscopic mucosal resection in seven. Two hundred thirty-one patients received adjuvant chemotherapy such as tegafur-uracil. After surgery, 142 patients developed local recurrence and/or new distant metastases, and 172 patients died during the median follow-up period of 49.41 months.

Evaluation of the neutrophil-to-lymphocyte ratio {#Sec4}
------------------------------------------------

In comparison of systemic inflammation response markers, there was a negative association between absolute neutrophil counts and absolute lymphocyte counts (Fig. [1](#Fig1){ref-type="fig"}).Figure 1Scatter plot of lymphocytes and neutrophils. The neutrophils population (%) is inversely proportional to the lymphocyte populations. There is a correlation between neutrophil and lymphocyte populations in the validation set using Pearson's correlation (−0.925, *p* \< 0.001) (alive: blue, dead: red).

We subsequently analysed survival using receiver operating characteristic (ROC) curves to evaluate the probability of iNLR and NLRc according to patient survival. The ROC curve revealed that the NLRc (area under the ROC curve, 0.674; sensitivity, 59.9%; specificity, 75.4%; positive predictive value, 14%, negative predictive value, 57.3%) had a greater predictive power for determining OS than the iNLR (area under the ROC curve, 0.584; sensitivity, 50%; specificity, 66.9%; positive predictive value, 18.6%, negative predictive value, 68.4%). Using DFS as the end point, the area under the ROC curve for the NLRc (area under the ROC curve, 0.637; sensitivity, 50%; specificity, 82.3%; positive predictive value, 12.7%, negative predictive value, 59.7%) was higher than that for iNLR (area under the ROC curve, 0.560; sensitivity, 47.2%; specificity, 65.4%; positive predictive value, 16.2%, negative predictive value, 75.4%) (Fig. [2](#Fig2){ref-type="fig"}).Figure 2Receiver operating characteristic (ROC) curve showing the statistical performance of the initial neutrophil-to-lymphocyte ratio (iNLR) (**a**) and the postoperative neutrophil-to-lymphocyte ratio change (NLRc) (**b**) depending on the disease-free and overall survival rate.

The NLRc was defined as negative (NLRc ≤ 0) when the postoperative NLR was lower than the preoperative NLR. The NLRc was defined as positive (NLRc \> 0) when the postoperative NLR was higher than the preoperative NLR.

Associations between the neutrophil-to-lymphocyte ratio change and clinicopathological parameters {#Sec5}
-------------------------------------------------------------------------------------------------

We analysed clinicopathological differences between patients with a negative and positive NLRc. The positive NLRc correlated to advanced AJCC stage (I, II *vs*. III; OR, 1.57; 95% CI: 1.12--2.2; *P* = 0.008), high T stage (1 *vs*. 2, 3, 4; OR, 1.39; 95% CI, 1.02--1.88; *P* = 0.037), high N stage (0, 1 *vs*. 2, 3; OR, 1.69; 95% CI, 1.21--2.36; *P* = 0.002), local recurrence (OR: 3.44, 95% CI: 1.55--7.62, *P* = 0.001), distant metastasis (OR: 2.79, 95% CI: 1.83--4.05, *P* \< 0.001), perineural invasion (OR: 1.57, 95% CI: 1.08--2.29, *P* = 0.019), and administration of adjuvant chemotherapy (OR: 1.55, 95% CI: 1.125--2.15, *P* = 0.007) (Table [1](#Tab1){ref-type="table"}). In addition, a positive NLRc was frequently observed in patients with AGC than in those with EGC (OR, 1.41; 95% CI, 1.04--1.91; *P* = 0.028). In comparisons of clinicopathological parameters between AGC and EGC, AGC was associated with high N stage (0, 1 *vs*. 2, 3; OR, 46.7; 95% CI, 24.7--88.29; *P* \< 0.001), large tumour size (≤3 *vs*. \>3 cm; OR, 10.9; 95% CI, 7.62--15.59; *P* \< 0.001), tumour location (cardia fundus, body *vs*. antrum, pylorus; OR, 0.68; 95% CI, 0.51--0.91; *P* = 0.009), advanced histological grade (well, moderately *vs*. poorly, signet ring; OR, 2.52; 95% CI, 1.87--3.39; *P* \< 0.001), diffuse type (OR, 2.26; 95% CI, 1.63--3.13; *P* \< 0.001), lymphovascular (OR, 9.41; 95% CI, 6.68--13.27; *P* \< 0.001) and perineural invasion (OR, 34.9; 95% CI, 16.02--76.06; *P* \< 0.001), and administration of adjuvant chemotherapy (OR, 2.55; 95% CI, 1.85--3.5; *P* \< 0.001).Table 1Association between clinicopathological parameters and the postoperative neutrophil-to-lymphocyte ratio change (NLRc) in 734 patients with gastric cancer.ParametersN = 734NLRc*p*-value (Chi-square)Negative (n = 483), %Positive (n = 251), %Sex Male499322 (66.7)177 (70.5)0.289 Female235161 (33.3)74 (29.5)Age (year)  ≤ 65366250 (51.8)116 (46.2)0.154 \>65368233 (48.2)135 (53.8)AJCC stage I418285 (59)133 (53)**0 008** ^1^ II11581 (16.8)34 (13.5) III201117 (24.2)84 (33.5)T criteria 1393272 (56.3)121 (48.2)**0 037** ^2^ 26440 (8.3)24 (9.6) 3171104 (21.5)67 (26.7) 410667 (13.9)39 (15.5)N criteria 0445307 (63.6)138 (55)**0 002** ^3^ 18459 (12.2)25 (10) 27251 (10.6)21 (8.4) 313366 (13.7067 (26.7)Tumour location Cardia or fundus3725 (5.2)12 (4.8)0.272^4^ Body317215 (44.5)102 (40.6) Antrum or pylorus380243 (50.3)137 (54.6)Local recurrence Absence707473 (97.9)234 (93.2)**0 001** Presence2710 (2.1)17 (6.8)Distant metastasis Absence614428 (88.6)186 (74.1)**\<0 001** Presence12055 (11.4)65 (25.9)Tumour size ≤3 cm323221 (45.8)102 (40.6)0.185 \>3 cm411262 (54.2)149 (59.4)Lauren type Intestinal396271 (56.1)125 (49.8)0.066^5^ Mixed217132 (27.3)85 (33.9) Diffuse12180 (16.6)41 (16.3)Histological grade Well13598 (20.3)37 (14.7)0.06^6^ Moderately225151 (31.3)74 (29.5) Poorly266161 (33.3)105 (41.8) Signet ring10873 (15.1)35 (13.9)Lymphatic invasion Negative437291 (60.2)146 (58.2)0.586Positive297192 (39.8)105 (41.8)Vascular invasion Negative640423 (87.6)217 (86.5)0.666 Positive9460 (12.4)34 (13.5)Perineural invasion Negative596404 (83.6)192 (76.5)**0 019** Positive13879 (16.4)59 (23.5)Adjuvant chemotherapy absence503347 (71.8)156 (62.2)**0 007** presence231136 (28.2)95 (37.8)Margin Uninvolved714472 (97.7)242 (96.4)0.302 involved2011 (2.3)9 (3.6)AJCC, American Joint Committee on Cancer, 8th edition.^1^I, II versus III.^2^T 1 versus 2, 3, 4.^3^N 0, 1 versus 2, 3.^4^Cardia, fundus, body versus antrum, pylorus.^5^ intestinal, mixed versus diffuse.^6^well, moderately versus poorly, signet ring.*p* \< 0.05 is shown in bold.

Differences in disease-free and overall survival according to the neutrophil-to-lymphocyte ratio change {#Sec6}
-------------------------------------------------------------------------------------------------------

Based on previous studies^[@CR18],[@CR19]^, the cut-off values of iNLR were \<3 and ≥3. The iNLR was significantly related to overall survival (OS) (HR, 1.74; 95% CI, 1.22--2.48; *P* = 0.002), but not to disease-free survival (DFS) (HR, 1.38; 95% CI, 0.91--2.09; *p* = 0.128). After adjustment for confounders including age, T and N criteria, lymphovascular and perineural invasion, and margin involvement, there was no significant relationship between iNLR and DFS or OS (multivariate DFS HR, 0.8; 95% CI, 0.52--1.23; *p* = 0.306 and OS HR, 1.07; 95% CI, 0.74--1.54; *p* = 0.732) (Table [2](#Tab2){ref-type="table"}).Table 2Disease-free and overall survival analyses according to initial neutrophil-to-lymphocyte ratio (iNLR) and neutrophil-to-lymphocyte ratio change (NLRc) in 734 patients with gastric cancer.SurvivalUnivariate^1^Multivariate^2^HR95% CILowerUpper**Disease-free survival** iNLR (\<3 vs. ≥3)0.1280.3060.80.5231.226 Age (≤65 vs. \>65)0.1290.441.1430.8151.602 T criteria (1, 2 vs. 3, 4)**\<0.001\<0.001**5.313.0369.289 N criteria (0, 1 vs. 2, 3)**\<0.001\<0.001**2.3341.4893.659 Lymphovascular invasion (absence vs. presence)**\<0.0010.019**1.6631.0882.542 Perineural invasion (absence vs. presence)**\<0.001**0.1471.3250.9061.938 Margin involvement (absence vs. presence)0.1240.0862.2160.8945.492**Disease-free survival** NLRc (negative vs. positive)**\<0.001\<0.001**2.5331.8023.562 Age (≤65 vs. \>65)0.1290.8371.0360.741.45 T criteria (1, 2 vs. 3, 4)**\<0.001\<0.001**5.4123.0929.472 N criteria (0, 1 vs. 2, 3)**\<0.0010.003**21.2693.153 Lymphovascular invasion (absence vs. presence)**\<0.0010.002**1.9461.2692.986 Perineural invasion (absence vs. presence)**\<0.001**0.5021.1410.7761.678 Margin involvement (absence vs. presence)0.1240.1781.870.7524.65**Overall survival** iNLR (\<3 vs. ≥3)**0.002**0.7321.0660.7391.537 Age (≤65 vs. \>65)**0.0010.005**1.5591.1422.127 T criteria (1, 2 vs. 3, 4)**\<0.0010**3.4662.2025.457 N criteria (0, 1 vs. 2, 3)**\<0.0010.001**1.9951.3312.991 Lymphovascular invasion (absence vs. presence)**\<0.001**0.0531.440.9952.085 Perineural invasion (absence vs. presence)**\<0.001**0.381.1790.8161.702 Margin involvement (absence vs. presence)**0.0010.001**3.1311.5826.196**Overall survival** NLRc (negative vs. positive)**\<0.001\<0.001**1.4481.0621.974 Age (≤65 vs. \>65)**0.001**0.0191.4481.0621.974 T criteria (1, 2 vs. 3, 4)**\<0.001\<0.001**3.552.2545.591 N criteria (0, 1 vs. 2, 3)**\<0.001**0.0131.681.1142.532 Lymphovascular invasion (absence vs. presence)**\<0.0010.003**1.7591.2142.548 Perineural invasion (absence vs. presence)**\<0.001**0.8231.0430.721.512 Margin involvement (absence vs. presence)**0.0010.006**2.6391.3285.245^1^Log rank test.^2^Cox proportional hazard model.*p* \< 0.05 is shown in bold.

In univariate analyses of the NLRc, there was a significant difference in DFS (HR, 2.97; 95% CI, 2.13--4.14; *p* \< 0.001) and OS (HR, 3.55; 95% CI, 2.61--4.81; *p* \< 0.001) between the negative and positive groups. In multivariate analyses, positive NLRc was associated with worse DFS (HR, 2.53; 95% CI, 1.8--3.56; *p* \< 0.001) and OS (HR, 1.45; 95% CI, 1.06--1.97; *p* \< 0.001) (Fig. [3](#Fig3){ref-type="fig"}).Figure 3Disease-free and overall survival analysis according the initial neutrophil-to-lymphocyte ratio (iNLR) (**a**,**b**) and postoperative neutrophil-to-lymphocyte ratio change (NLRc) (**c**,**d**). Abbreviations: n.censor, number of censored subjects.

In univariate and multivariate analyses according to the Lauren classification, a positive NLRc was associated with poor DFS and OS in patients with intestinal (univariate DFS HR, 3.4; 95% CI, 2.04--5.65; *p* \< 0.001 and OS HR, 4.34; 95% CI, 2.72--6.95; *p* \< 0.001; multivariate DFS HR, 3.25; 95% CI, 1.91--5.52; *p* \< 0.001 and OS HR, 4.56; 95% CI, 2.81--7.4; *p* \< 0.001), diffuse (univariate DFS HR, 2.78; 95% CI, 1.62--4.79; *p* \< 0.001 and OS HR, 3.53; 95% CI, 2.1--6.01; *p* \< 0.001; multivariate DFS HR, 2.52; 95% CI, 1.42--4.49; *p* \< 0.001 and OS HR, 2.92; 95% CI, 1.67--5.1; *p* = 0.002), or mixed type (univariate DFS HR, 2.28; 95% CI, 1.1--4.86; *p* = 0.028 and OS HR, 2.39; 95% CI, 1.25--4.56; *p* = 0.007; multivariate DFS HR, 2.52; 95% CI, 1.1--5.79; *p* = 0.013 and OS HR, 2.45; 95% CI, 1.21--4.97; *p* = 0.029) (Fig. [4](#Fig4){ref-type="fig"}).Figure 4Disease-free survival (**a**,**b**,**c**) and overall survival (**d**,**e**,**f**) curves showing the association between the postoperative neutrophil-to-lymphocyte ratio change (NLRc) according to the Lauren classification, which includes intestinal, diffuse, and mixed type (all *p* \< 0.05).

In univariate and multivariate analyses according to histological grade, there were significant associations between NLRc and DFS and OS in patients with well (univariate DFS HR, 4.84; 95% CI, 1.72--13.64; *p* = 0.001 and OS HR, 4.01; 95% CI, 1.49--10.77; *p* = 0.003; multivariate DFS HR, 11.55; 95% CI, 2.89--46.15; *p* = 0.001 and OS HR, 5.82; 95% CI, 1.76--19.22; *p* = 0.004), poorly differentiated (univariate DFS HR, 2.52; 95% CI, 1.57--4.04; *p* \< 0.001 and OS HR, 3.42; 95% CI, 2.2--5.29; *p* \< 0.001; multivariate DFS HR, 2.36; 95% CI, 1.45--3.85; *p* = 0.001 and OS HR, 2.91; 95% CI, 1.86--4.56; *p* \< 0.001), or signet ring cell types (univariate DFS HR, 3.83; 95% CI, 1.56--9.38; *p* = 0.002 and OS HR, 2.73; 95% CI, 1.05--7.08; *p* = 0.031; multivariate DFS HR, 3.94; 95% CI, 1.53--10.1; *p* = 0.004 and OS HR, 2.74; 95% CI, 1.01--7.42; *p* = 0.048). In univariate analyses of moderate histological grade, the NLRc was statistically related to DFS and OS (DFS HR, 2.48; 95% CI, 1.3--4.74; *p* = 0.004 and OS HR, 3.39; 95% CI, 1.94--5.91; *p* \< 0.001). In multivariate analyses of moderate histological grade, the NLRc was statistically related to OS (HR, 3.84; 95% CI, 2.14--6.88; *p* \< 0.001) but not to DFS (HR, 1.94; 95% CI, 0.98--3.83; *p* = 0.057) (Fig. [5](#Fig5){ref-type="fig"}).Figure 5Disease-free survival (**a**,**b**,**c**,**d**) and overall survival (**e**,**f**,**g**,**h**) showing the association between the postoperative neutrophil-to-lymphocyte ratio change (NLRc) according to the histological grade, which includes well, moderately, poorly differentiated and signet ring cell type (all *p* \< 0.05).

In univariate and multivariate analyses according to adjuvant chemotherapy, there were significant associations between the NLRc and DFS or OS in patients receiving adjuvant chemotherapy (univariate DFS HR, 5.93; 95% CI, 3.3--10.64; *p* \< 0.001 and OS HR, 4.62; 95% CI, 2.74--7.79; *p* \< 0.001; multivariate DFS HR, 6.36; 95% CI, 3.47--11.67; *p* \< 0.001 and OS HR, 4.93; 95% CI, 2.87--8.47; *p* \< 0.001). In univariate analyses of patients not receiving adjuvant chemotherapy, the NLRc was linked to poor DFS and OS (DFS HR, 1.77; 95% CI, 1.14--2.76; *p* = 0.011 and OS HR, 2.9; 95% CI, 1.97--4.27; *p* \< 0.001). In multivariate analyses, a positive NLRc was associated with poor OS (HR, 4.93; 95% CI, 2.87--8.47; *p* \< 0.001) but not with worse DFS, (HR, 1.13; 95% CI, 0.71--1.8; *p* = 0.602) (Table [3](#Tab3){ref-type="table"}).Table 3Disease-free and overall survival analyses according to the NLR change based on the Lauren classification.SurvivalUnivariate^1^Multivariate^2^HR95% CILowerUpper**Disease-free survival** Lauren classification  Intestinal type**\<0.001\<0.001**3.2481.9135.516  Diffuse type**\<0.001\<0.001**2.5241.4184.493  Mixed type**0.0280.013**2.5221.0985.79 Histological grade  Well**0.0010.001**11.5452.88846.146  Moderately**0.004**0.0571.9380.983.834  Poorly**\<0.0010.001**2.3631.4533.845  Signet ring**0.0020.004**3.9351.53410.096 Adjuvant chemotherapy  Not received**0.01**0.6021.1310.7121.797  Received**\<0.001\<0.001**6.363.46611.67**Overall survival** Lauren classification  Intestinal type**\<0.001\<0.001**4.5622.8127.4  Diffuse type**\<0.0010.002**2.9231.6725.107  Mixed type**0.0070.029**2.4531.2124.966 Histological grade  Well**0.0030.004**5.821.76319.22  Moderately**\<0.001\<0.001**3.8382.1416.879  Poorly**\<0.001\<0.001**2.911.8574.558  Signet ring**0.0310.048**2.7361.0097.423 Adjuvant chemotherapy  Not received**\<0.001\<0.001**2.2571.5173.356  Received**\<0.001\<0.001**4.9342.8738.473^1^log rank test.^2^Cox proportional hazard model; adjusted for age, T and N criteria, lymphovascular and perineural invasion, and margin status.*p* \< 0.05 is shown in bold.^1^log rank test.^2^Cox proportional hazard model; adjusted for age, T and N criteria, lymphovascular and perineural invasion, and margin status.*p* \< 0.05 is shown in bold.

Discussion {#Sec7}
==========

The systemic inflammatory reaction in the tumour microenvironment is essential for cancer growth and development. The concept of inflammation-based scores has been applied in many types of cancer. Neutrophils are thought to play a key role in normal physiological angiogenesis and tumour angiogenesis^[@CR20],[@CR20]^. Activated neutrophils can release matrix metalloproteinases (MMPs), in particular MMP-9, which activate potent angiogenic factors (vascular endothelial growth factor, fibroblast growth factor-2)^[@CR21],[@CR22]^. The increase in neutrophil count leads to induction of tumour progression and development of metastases via secretion of cytokines (tumor necrosis factor, IL-1, IL-6)^[@CR23],[@CR24]^. In contrast, lymphocytes are a major factor for the suppression of cancer progression. Cytotoxic lymphocytes, which are ultimately responsible for killing tumour cells and eradicating the tumour, are applicable to cancer immunotherapy^[@CR25]^. Based on the opposite functions of neutrophils and lymphocytes, the NLR might provide improved prognostic information regarding cancer progression.

The NLRc is a readily available and inexpensive biomarker for differential types of cancer. Nevertheless, the precise mechanisms by which the relationship between neutrophils and lymphocytes might predict clinical outcomes are not fully understood. A study by El-Hag *et al*. demonstrated that neutrophils lead to suppression of the cytolytic activity of immune cells such as lymphocytes, natural killer cells, and activated T cells^[@CR26]^. In our results, a negative correlation between neutrophils and lymphocytes supports the above concept. Other published data have described several mechanisms in detail as follows: First, the anticancer responses of natural killer cells and activated T cells might be suppressed by marked neutrophil infiltration around the tumour^[@CR27]^. Therefore, a high NLR might decrease the effects of the lymphocyte-mediated cellular immune response and promote cancer progression. Second, circulating neutrophils contribute to tumour growth and progression by producing cytokines. Considering the complexity and heterogeneity of cancer, the neutrophil count alone might not reflect a decreased lymphocyte-mediated immune response, and a low lymphocyte count alone might not reflect the neutrophil-driven tumour growth process. In addition, a study by Kobayashi *et al*. suggested that the NLR represents the relative extent of inflammation and host immunity against cancer, as its value is directly affected by the total count of neutrophils and lymphocytes. The combined effects of neutrophilia and lymphocytopenia might be better than the effect of a single marker for predicting clinical outcome.

In gastric cancer, a previous study reported the role of the iNLR without evaluation of the NLRc^[@CR14],[@CR18],[@CR19]^. These studies focused only on the iNLR, not on the dynamic changes in the NLR after treatment. In different types of cancer, few studies have evaluated dynamic changes in the NLR after treatment. In studies of renal cell carcinoma, a negative NLRc was associated with favourable outcomes^[@CR28]^. Another study demonstrated that the NLRc is related to clinicopathological parameters such as recurrence, tumour size, and stage^[@CR29]^. In studies of non-small cell lung cancer and urothelial carcinoma, the NLRc had a greater statistical power than the iNLR in evaluating patient survival^[@CR30],[@CR31]^. A positive NLRc indicates that the microenvironment supporting cancer growth is persistent, despite removing the causal risk factor related to inflammation after cancer treatment. Therefore, the NLRc after treatment is more meaningful than the iNLR at the time of the first diagnosis, because the NLRc reflects the dynamic change of the immune response after treatment. In our study, a positive NLRc had more statistical power than iNLR in predicting DFS and OS.

In summary, the NLRc is statistically associated with increased mortality rates in patients with gastric cancer and has better statistical power than the iNLR. Compared to molecular markers, the NLRc seems to be a convenient, easily obtainable and repeatable, low cost, and reliable predictor for patients with gastric cancer. Practically, this concept of the NLRc could provide clear, concise, and easily applicable information for evaluating prognosis in gastric cancer, which comprises a heterogeneous cancer cell population. Larger scale studies are required to better assess the relationships between the NLRc and prognosis of other types of cancer.

Materials and Methods {#Sec8}
=====================

Patient selection {#Sec9}
-----------------

This retrospective study included 734 patients diagnosed with gastric adenocarcinoma at two hospitals between 2000 and 2013. The Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) criteria were followed throughout this study. The inclusion criteria were: 1) patients with histopathological evidence of primary adenocarcinoma confirmed by pathologists, and known clinical outcome; and 2) patients with postoperative follow-up blood samples, which were collected in ethylenediaminetetraacetic acid-containing tubes according to other published studies^[@CR32]^. The exclusion criteria were: patients diagnosed with adenocarcinoma but with inadequate clinical history and/or no available microscopic slides.

Interpretation of the neutrophil-to-lymphocyte ratio {#Sec10}
----------------------------------------------------

Total white blood cells (WBCs), neutrophils, and lymphocytes were obtained by complete blood counts before surgery. A follow-up blood sample was obtained at 3--6 months after surgery.

The absolute neutrophil and lymphocyte counts were calculated by multiplying the percentage of each component by number of WBCs. The neutrophil-to-lymphocyte ratio was determined from the differential count by dividing the absolute neutrophil count by the absolute lymphocyte count. To evaluate the NLRc, we subtracted the postoperative NLR from the preoperative NLR: postoperative NLR -- preoperative NLR = NLR change.

Statistical analysis {#Sec11}
--------------------

The associations between clinicopathological parameters and the NLRc were analysed by the chi-square test. The DFS time was defined as the time from the date of diagnosis to the date of local recurrence or new distant metastasis. The OS time was defined as the time from the date of diagnosis to all-cause death. Survival curves were generated using the Kaplan-Meier method and were compared by the log rank test. A Cox regression model was used for multivariate analysis. A p-value \< 0.05 was considered statistically significant. All statistical analyses were performed using SPSS statistics (version 20.0, Chicago, IL, USA) and R packages (<http://www.r-project.org/>).
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